Compare Amylx Pharmaceuticals Inc (AMLX) vs Li Auto Inc (LI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Li Auto Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Li Auto Inc trades at $12.02 (market cap $11.97B). The key difference: Li Auto Inc is far larger — about 6× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | LI | |
|---|---|---|
Market Cap | $1.98B | $11.97B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $31.80 |
52-Week Low | $7.64 | $11.74 |
Enterprise Value | $1.70B | $888.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Li Auto (LI) trades at $12.10, down 1.6% with a bearish technical signal. Recent earnings show volatility with Q1 2026 missing estimates, while cash flow turned negative in 2025. The company faces intense competition and margin pressure, though analyst consensus remains cautiously optimistic with a $14.80 price target. Vehicle deliveries reached 30,895 in June 2026, indicating steady demand despite market headwinds.
Outlook hinges on execution of L series models and recovery from 2025-2026 trough years. Risks include aggressive discounting, regulatory challenges, and macroeconomic pressures in China's EV market. The stock presents a speculative opportunity if operational improvements materialize, but near-term volatility is expected.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
